Pfizer-partnered Zentalis woos new CEO, cobbles together $200M
Ready to transform itself into a serious mid- to late-stage cancer player that could take on rivals as big as AstraZeneca, a Pfizer-partnered biotech is embracing some big changes.
Eli Lilly vet Kim Blackwell is succeeding Anthony Sun as CEO of Zentalis. Sun, a former VC at Aisling who co-founded Zentalis in 2015, will remain at the helm of its Asia-focused joint venture, Zentera.
Blackwell’s mandate will be to speed up the development of the two lead candidates. Zentalis has also raised $200 million from an underwritten offering that priced its stock at $19.38 per share.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.